标准口服补液盐治疗严重急性营养不良伴中重度脱水:GASTROSAM 2期试验
GASTROSAM 是一项在四个非洲国家六家医院开展的2期、开放标签、优效性随机对照试验,纳入415名6月龄至12岁严重急性营养不良伴腹泻及中重度脱水的儿童。结果显示,世界卫生组织口服补液盐(WHO-ORS)与用于营养不良的低钠补液盐(ReSoMal)在24小时血钠变化和28天死亡率上均无显著差异,且未观察到液体超负荷事件。
要点
- 研究中未观察到肺水肿或心负荷过重等液体超负荷事件。
核心结论
- WHO-ORS与ReSoMal在严重急性营养不良伴中重度脱水患儿中产生相似的结局,且均未导致液体超负荷。
研究设计与样本
- GASTROSAM为2期、析因、开放标签、优效性随机对照试验,在肯尼亚、尼日尔、尼日利亚和乌干达六家医院开展。
- 纳入415名6月龄至12岁严重急性营养不良伴腹泻及重度(A层)或中度(B层)脱水的住院儿童,按1:1随机分配接受ReSoMal或低渗WHO-ORS。
- 主要终点为全部随机参与者24小时血钠浓度较基线的变化,按意向性治疗分析。
主要发现
- 主动监测的液体超负荷事件(肺水肿和心负荷过重)均未观察到。
临床怎么用
- 对于严重急性营养不良伴中重度脱水的腹泻患儿,WHO-ORS可考虑作为ReSoMal的替代选择,二者安全性及有效性相似。
局限性
- 本研究为2期开放标签试验,样本量有限,需进一步验证。
- 有生活经验的儿童未参与研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: International guidelines for treatment of children with severe acute malnutrition advise against giving standard oral rehydration solutions (ORS) for dehydration secondary to diarrhoea. Instead, they recommend exclusive use of low-sodium rehydration solution for malnutrition (ReSoMal), due to concerns about both sodium and fluid overload. Supportive evidence is lacking, warranting reappraisal of this guidance. We aimed to assess the safety and superiority of standard WHO-ORS versus ReSoMal. METHODS: GASTROSAM was a phase 2, factorial, open-label, superiority randomised controlled trial conducted at six hospitals in four African countries (Kenya, Niger, Nigeria, and Uganda). Children aged 6 months to 12 years with severe acute malnutrition who were admitted to hospital with severe (stratum A) or moderate (stratum B) dehydration and diarrhoea were randomly assigned in a 1:1 ratio to receive ReSoMal or low-osmolarity WHO-ORS. A simultaneous randomisation in stratum A compared two intravenous strategies versus an oral control rehydration strategy (results reported elsewhere). Children with severe dehydration (stratum A) received their allocated ORS as soon as possible. The primary endpoint was change in sodium concentration at 24 h from baseline in all randomised participants and analysed on an intention-to-treat basis. Children with lived experience were not involved in the study design. The trial is registered on the ISRCTN registry (ISRCTN76149273) and the Pan-African Clinical Trials Registry (PACTR202103852542919). FINDINGS: Between Sept 2, 2019, and Oct 27, 2024, 415 eligible children were enrolled (218 [53%] male; 197 [47%] female); 272 were enrolled into stratum A (137 to ReSoMal and 135 to WHO-ORS) and 143 were enrolled into stratum B (69 to ReSoMal and 74 to WHO-ORS). Children were followed up for 28 days; 11 (3%) were lost to follow-up or withdrew. The primary endpoint was assessed in 387 (93%) of 415 participants. The increase in sodium concentration was similar in both groups (5·3 mmol/L [SD 8·1] with ReSoMal vs 5·0 mmol/L [7·6] with WHO-ORS; mean difference for WHO-ORS vs ReSoMal -0·6 [95% CI -1·9 to 0·7], p=0·37). There was no difference in day 28 mortality between the WHO-ORS and ReSoMal groups (19 [9%] vs 24 [12%]; adjusted hazard ratio 0·76 [95% CI 0·41 to 1·41], p=0·39). Fluid overload events (pulmonary oedema and cardiac overload) were actively monitored: none was observed. INTERPRETATION: WHO-ORS resulted in similar outcomes to ReSoMal, and neither strategy led to fluid overload. This finding informs the simplification of guidelines supporting the use of WHO-ORS for the management of dehydration in children regardless of nutritional status. FUNDING: Joint Global Health Trials Scheme of the UK Medical Research Council, UK Department for International Development, Wellcome, and Médecins Sans Frontières.
引用
- Maitland K, Sainna H, Connon R, et al. Oral rehydration for severe malnutrition in children with moderate and severe dehydration (GASTROSAM): a phase 2, open-label, superiority randomised controlled trial. Lancet Child Adolesc Health. 2026. PMID: 41825474. doi:10.1016/S2352-4642(25)00371-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。